ACLX-002 is a gene-modified cell therapy commercialized by Arcellx, with a leading Phase I program in Myelodysplastic Syndrome. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of ACLX-002’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for ACLX-002 is expected to reach an annual total of $22 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

ACLX-002 Overview

ACLX-002 is under development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). The immune cell therapy consists of antigen receptor complex T cells (ARC-T) that kills the tumor cells. It acts by targeting cells expressing CD123.The drug candidate is being developed based on ARC-SparX platform.

Arcellx Overview

Arcellx is a biopharmaceutical company which develops, manufactures and markets novel and adaptive cell therapies for the treatment of cancer, acute myeloid leukemia, solid tumors and autoimmune diseases. Arcellx is headquartered in Gaithersburg, Maryland, the US.

The operating loss of the company was US$65 million in FY2021, compared to an operating loss of US$32.1 million in FY2020. The net loss of the company was US$65 million in FY2021, compared to a net loss of US$32.1 million in FY2020.

For a complete picture of ACLX-002’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.